Ardelyx (ARDX) vs Bicara Therapeutics (BCAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bicara Therapeutics (BCAX) has outperformed Ardelyx (ARDX) over the past year, losing 4.1% versus a loss of 35.4%. Bicara Therapeutics is the larger company by market cap ($1.14 billion vs $844.3 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | BCAX |
|---|---|---|
| Share price | $3.27 | $17.26 |
| Market cap | $844.27M | $1.14B |
| 1-day change | +0.31% | +5.12% |
| YTD return | -43.91% | +2.55% |
| 1-year return | -35.38% | -4.11% |
| 5-year return | +202.78% | — |
| Forward P/E | 11.26 | — |
| EPS (TTM) | $-0.23 | $-3.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $30.99 |
| 52-week low | $3.18 | $13.70 |
| Distance from 52-week high | -61.07% | -44.30% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +294.50% | +105.68% |
| Average volume | 4.17M | 623.17K |
| Shares outstanding | 258.19M | 66.17M |
| Employees | 489 | 103 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCAX has outperformed ARDX by 31.3 percentage points over the past year.
- The two companies sit in different sectors: Ardelyx in Health Care and Bicara Therapeutics in Healthcare.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Healthcare · Biotechnology · 103 employees
ARDX vs BCAX FAQ
Which is bigger, Ardelyx or Bicara Therapeutics?
Bicara Therapeutics (BCAX) is larger, with a market capitalization of $1.14B compared with $844.27M for Ardelyx (ARDX).
Which stock has performed better over the past year, ARDX or BCAX?
BCAX returned -4.11% over the past 12 months, compared with -35.38% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Bicara Therapeutics in the same industry?
No. Ardelyx is in the Health Care sector, while Bicara Therapeutics is in Healthcare.